(MedPage Today) — After a period of relative inactivity, therapeutic development in HER2-positive gastroesophageal adenocarcinoma (GEA) has evolved rapidly over the past 5 years, establishing a new standard of care that was supplanted by another…
Source link
Progress in HER2-Positive Gastroesophageal Adenocarcinoma
